Table 1.
Comparison of demographics, comorbidities, clinical features at baseline and follow-up after at least one year of endoscopic sinus surgery among patients with different level of disease control according to the EPOS 2012 classification system.
| Controlled# | Partly controlled | Uncontrolled | |
|---|---|---|---|
| Subject, n (%) | 74 (40.4) | 56 (30.6) | 53 (29.0) |
| Male n, (%) | 48 (64.9) | 40 (71.4) | 35 (66.0) |
| Age, mean (SD) | 39.7 (14.6) | 37.7 (13.7) | 40.3 (11.7) |
| Weeks after surgery, median (IQR) | 91.4 (80.5) | 72.6 (44.3) | 70.6 (79.1) |
| Current smoker, n (%) | 9 (12.2) | 6 (10.7) | 3 (5.7) |
| Allergic rhinitis, n (%) | 7 (9.5) | 2 (3.6) | 11(20.8)$ |
| Asthma, n (%) | 6 (8.1) | 7 (12.5) | 10(18.9)$ |
| Prior sinus surgery, n (%) | 17 (23.0) | 23(41.1)$ | 17 (32.1) |
| Preoperative L-K endoscopic score, median (IQR) | 8.0 (4.0) | 9.0 (3.0) | 9.0 (3.0) |
| Preoperative L-M CT score, median (IQR) | 14.0 (7.0) | 15.0 (9.0) | 17.0(8.0)$ |
| Blood eosinophil count, median (IQR) ( × 109/L) | 0.17 (0.21) | 0.29(0.32)$ | 0.33(0.37)* |
| Blood eosinophil percentage, median (IQR) (%) | 2.1 (3.0) | 3.65(5.35)$ | 4.8(6.3)* |
| Tissue eosinophil count, median (IQR) (/HPF) | 22.0 (40.25) | 27.5 (69.25) | 63.0(139.5)€ |
| Tissue eosinophil percentage, median (IQR) (%) | 5.2 (19.8) | 9.3 (32.6) | 19.4(37.9)* |
| Post-operative TNSS, median (IQR) | 0.0 (1.0) | 2.0(1.0)€ | 4.0(2.0)€ |
| Medication length >6 months after surgery, n (%) | 28 (37.8) | 38(67.9)€ | 33(62.3)* |
#Comparator group; Results in boldface indicate a P value of less than 0.05. $P < 0.05; *P < 0.01; €P < 0.001.
SD, standard deviation; IQR, interquartile range; L-K, Lund-Kennedy; L-M, Lund-Mackay; CT, computed tomography; HPF, high power field; TNSS, total nasal symptom score.